Comparing the current results to its competitors, Elanco Animal Health Incorporated reported Revenue increase in the 2 quarter 2026 by 10.23 % year on year. The sales growth was above Elanco Animal Health Incorporated's competitors' average revenue growth of 4.99 %, achieved in the same quarter.
Elanco Animal Health Incorporated Net Income in the 2 quarter 2026 grew year on year by 390.91%, while most of its competitors have experienced a net loss.
Elanco Animal Health Incorporated's Comment on Competition and Industry Peers
The company operates in a highly competitive global market, with competition varying by region, species, product category, and individual product. Competitive factors include product quality, price, cost-effectiveness, promotional effectiveness, new product development, and product differentiation. Its products compete with both branded and generic products currently available or introduced by competitors. New products offering advantages in ease of use, therapeutic benefits, or cost may result in reduced sales or price pressures. Primary competitors include Zoetis Inc., Boehringer Ingelheim Animal Health GmbH (the animal health division of Boehringer Ingelheim GmbH), and Merck Animal Health (the animal health division of Merck & Co., Inc.). The company also faces competition from various other animal health product manufacturers worldwide, including start-ups, generic drug manufacturers, and producers of nutritional products.
Company's competitiveness improved within Overall company, with revenue growth of 10.23 % and its market share increased to approx. 5.25 %. << More on ELAN Market Share.
*Market share is calculated based on total revenue.
News about Elanco Animal Health Incorporated Contracts
October 10, 2024
In an alarming development in the realm of securities regulation, Gainey McKenna and Egleston announced the filing of a class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN) in the United States District Court for the District of Maryland. This legal action comes on behalf of individuals and entities who purchased or otherwise acquired Elanco securities between November 7, 2023, and June 26, 2024, which is referred to as the “Class Period.” The lawsuit is grounded in allegations that may have far-reaching implications not only for investors but also for the pharmaceutical and animal health industries as a whole. Background of Elanco Animal HealthElanco Animal Health is a global lea...
Publicly Traded Peers of Elanco Animal Health Incorporated
Viatris Inc Share Performance
+3.28%
This Quarter
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Zoetis Inc operates as a global animal health company, offering a comprehensive range of medicines, vaccines, diagnostics, and services for both livestock and companion animals. Their business model emphasizes innovation in research and development to improve animal health, coupled with strong customer support, educational resources, and targeted solutions for veterinarians, livestock producers, and pet owners around the world.
Phibro Animal Health Corporation Share Performance
-5.36%
This Year
Phibro Animal Health Corporation
Profile
Phibro Animal Health Corporation is a leading global provider of animal health and nutrition products, catering to both livestock and companion animals. Their business model centers around producing and marketing a wide range of pharmaceuticals, vaccines, nutritional supplements, and other animal health products. They aim to serve the diverse needs of farmers, veterinarians, and pet owners, while focusing on innovation, quality, and customer satisfaction.
Sources:
Elanco Animal Health Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Elanco Animal Health Incorporated versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
